Healthcare sector | Drug Manufacturers - General industry
| Price | $7.19 |
|---|---|
| Shares Outstanding | 260.32M |
| All-Time Low | $6.18 |
| 52-Week Low | $6.18 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-29.86 |
| Net Tangible Assets / Share | $0 |
| Shares Outstanding Ave Change (Annual) | 0.56% |
| Shares Δ YoY | 0.85% |
| Avg CA Burn (Annual %) | 5.23% (as of 3-1-2026) |
| Avg CA Burn (Quarterly %) | 0.14% (as of 3-1-2026) |
| Max Earning Power / Share | $2.53 |
|---|---|
| Adjusted Earning Power |
$-7.51
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
5.07%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 1.7B (as of 3-1-2026) |
| Avg EBITDA (5Q) | 325.6M (as of 3-1-2026) |
| Avg Net Income (5Y) | 1B (as of 3-1-2026) |
| Avg Net Income (5Q) | 59.2M (as of 3-1-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | Yes | 3-1-2026 |
| Consecutive Years Paid | 6 years | 3-1-2026 |
| Pays Dividend | Yes | 3-1-2026 |
| Dividend Type | common | 3-1-2026 |
| Dividend Payout / Share | $0.02 | 3-1-2026 |
| Last Dividend Date | 3-11-26 | |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | Yes | 3-1-2026 |
| Net Income Positive | No | 3-1-2026 |
| Current Dividend Streak | Yes | 3-1-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $-17.41 | -4.5B ($-4,531,000,000) | 260.3M (260,316,000) |
| 2025-09-30 | Quarterly | $-19.67 | -5.1B ($-5,114,000,000) | 260M (259,983,000) |
| 2025-06-30 | Quarterly | $-20.42 | -5.3B ($-5,309,000,000) | 260M (259,965,000) |
| 2025-03-31 | Quarterly | $-21.54 | -5.6B ($-5,555,000,000) | 258M (257,950,149) |
| 2024-12-31 | Quarterly | $-21.81 | -5.6B ($-5,622,000,000) | 257.8M (257,799,000) |
| 2024-12-31 | Annual | $-21.81 | -5.6B ($-5,622,000,000) | 257.8M (257,799,000) |
| 2024-09-30 | Quarterly | $-18.92 | -4.9B ($-4,873,000,000) | 257.5M (257,539,000) |
| 2023-12-31 | Annual | $-20.37 | -5.2B ($-5,206,000,000) | 255.6M (255,626,000) |
| 2022-12-31 | Annual | $-24.15 | -6.1B ($-6,144,000,000) | 254.4M (254,370,000) |
| 2021-12-31 | Annual | $-26.67 | -6.8B ($-6,762,000,000) | 253.6M (253,550,029) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 6.4B ($6,403,000,000) |
| 2023-12-31 | 6.3B ($6,263,000,000) |
| 2022-12-31 | 6.2B ($6,174,000,000) |
| 2021-12-31 | 6.3B ($6,304,000,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| 2026-02-23 | $0.02 |
| 2025-11-20 | $0.02 |
| 2025-08-15 | $0.02 |
| 2025-05-12 | $0.02 |
| 2025-02-24 | $0.28 |
| Date | Dividend / Share |
|---|---|
| 2024-11-12 | $0.28 |
| 2024-08-16 | $0.28 |
| 2024-05-10 | $0.28 |
| 2024-02-23 | $0.28 |
| 2023-11-10 | $0.28 |
| 2023-08-17 | $0.28 |
| 2023-05-12 | $0.28 |
| 2023-02-24 | $0.28 |
| 2022-11-10 | $0.28 |
| 2022-08-12 | $0.28 |
| 2022-05-13 | $0.28 |
| 2022-02-25 | $0.28 |
| 2021-11-19 | $0.28 |
| 2021-08-20 | $0.28 |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-03-02 | 260,315,650 | +332,738 |
Latest short-interest change: 17,545,543 shares (8.99% of float) | Days to cover: 2.80
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-02-26 | 17,545,543 shares | +3,152,497 | +21.90% |
| 2026-02-11 | 14,393,046 shares | -1,151,870 | -7.41% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.